GlassScriptPhysician profile
Penny Johnson
NPI 1821186735
$2,045.52
in general payments reported to CMS, 2019-2025
17 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $396 · 2023: $759 · 2024: $278 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $264.10 | 2021-2025 | |
| Amgen INC. | $244.93 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $233.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $219.72 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $212.94 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $155.70 | 2023 | Watchman Access System, Watchman |
| Merck Sharp & Dohme LLC | $151.32 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $139.17 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.56 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $74.38 | 2021-2023 | Brilinta |
| Lexicon Pharmaceuticals, INC. | $70.28 | 2024 | Inpefa |
| Medtronic, INC. | $37.22 | 2025 | Aurora Ev-Icd Mri Surescan, Linq II |
| Tactile Systems Technology INC | $36.02 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Scpharmaceuticals INC. | $30.52 | 2024-2025 | |
| Atricure, INC. | $23.81 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.82 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.